Figure 1
High-throughput drug screen using patient-derived material. Figure 1 highlights high-throughput screening approaches using patient tumour material. (1) represents in vitro culture of tumour explants (for example as organoids/tumoroids). (2) represents the integrated PDTX:PDTC platform developed by our lab. In this strategy, patient tumour material is passaged and maintained in the murine host, and patient-derived tumour cells (PDTCs) are periodically dissociated for short-term ex vivo culture and high-throughput drug screens.
